Omeros Narrows Losses, Secures Major Novo Nordisk Deal for Zaltenibart

TL;DR

**OMER is making a smart move by offloading zaltenibart to Novo Nordisk for a cash injection, but their dwindling cash reserves mean they need that deal to close ASAP.**

AI Summary

Omeros Corporation reported a net loss of $30.917 million for the three months ended September 30, 2025, a slight improvement from the $32.232 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $89.801 million, significantly better than the $125.457 million loss in the prior year. Research and development expenses decreased to $15.995 million for the quarter, down from $24.084 million in Q3 2024, and selling, general and administrative expenses also fell to $10.397 million from $11.323 million. A major strategic development is the Asset Purchase and License Agreement (APLA) with Novo Nordisk Health Care AG, signed on October 10, 2025, for zaltenibart, which is expected to close in Q4 2025. This deal includes $340.0 million in upfront and near-term milestone payments, with $240.0 million due at closing, and potential additional milestones up to $1.71 billion plus tiered royalties. The company's cash and cash equivalents decreased to $2.395 million as of September 30, 2025, from $3.400 million at December 31, 2024, and total current assets dropped from $134.120 million to $71.805 million over the same period. Omeros also paused its Phase 3 clinical development program for zaltenibart in PNH to prioritize capital for other programs.

Why It Matters

This filing reveals Omeros's strategic pivot, offloading zaltenibart to Novo Nordisk for a substantial upfront payment and future milestones, which is critical for its liquidity and continued operations given its declining cash position. For investors, this deal provides a much-needed cash infusion and validates a key pipeline asset, potentially de-risking OMER's future. Employees may see a shift in focus towards other pipeline candidates like narsoplimab. Competitively, this partnership with Novo Nordisk could accelerate zaltenibart's development and market penetration, intensifying competition in complement-mediated disease treatments.

Risk Assessment

Risk Level: high — The company's cash and cash equivalents are critically low at $2.395 million as of September 30, 2025, down from $3.400 million at December 31, 2024. The entire strategic outlook hinges on the closing of the Novo Nordisk APLA, which is subject to customary closing conditions, including regulatory approvals, and if it fails, Omeros faces significant liquidity challenges.

Analyst Insight

Investors should closely monitor the closing of the Novo Nordisk APLA, expected in Q4 2025, as the $240.0 million upfront payment is crucial for Omeros's financial stability. Consider this a speculative play on successful deal closure and future pipeline progress, particularly narsoplimab's regulatory path.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

$185.706M

total Debt

$256.591M

net Income

-$30.917M

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

$2.395M

revenue Growth

Not Disclosed

Key Numbers

• $30.917M — Net Loss (Q3 2025) (Improved from $32.232M in Q3 2024)
• $89.801M — Net Loss (YTD Q3 2025) (Improved from $125.457M in YTD Q3 2024)
• $15.995M — R&D Expenses (Q3 2025) (Decreased from $24.084M in Q3 2024)
• $10.397M — SG&A Expenses (Q3 2025) (Decreased from $11.323M in Q3 2024)
• $2.395M — Cash and Cash Equivalents (As of September 30, 2025, down from $3.400M at Dec 31, 2024)
• $340.0M — Upfront/Near-term Milestone Payments (Expected from Novo Nordisk APLA)
• $240.0M — Payment at APLA Closing (Expected from Novo Nordisk in Q4 2025)
• $1.71B — Total Potential Milestone Payments (From Novo Nordisk APLA, including development, approval, and sales milestones)
• 70,073,622 — Common Shares Outstanding (As of September 30, 2025, increased from 58,044,465 at Dec 31, 2024)
• (220,478) — Total Shareholders' Deficit (in thousands) (As of September 30, 2025, worsened from (182,609) at Dec 31, 2024)

Key Players & Entities

• Omeros Corporation (company) — clinical-stage biopharmaceutical company
• Novo Nordisk Health Care AG (company) — partner in Asset Purchase and License Agreement
• zaltenibart (product) — antibody targeting MASP-3
• narsoplimab (product) — antibody targeting MASP-2
• FDA (regulator) — U.S. Food and Drug Administration
• EMA (regulator) — European Medicines Agency
• $340.0 million (dollar_amount) — upfront and near-term milestone payments from Novo Nordisk
• $240.0 million (dollar_amount) — payment due at closing of Novo Nordisk Transaction
• $1.3 billion (dollar_amount) — potential sales-based milestone payments from Novo Nordisk
• $2.395 million (dollar_amount) — cash and cash equivalents as of September 30, 2025

FAQ

Risk Factors

• Deteriorating Shareholder Equity and Cash Position [high — financial]: The company's total shareholders' deficit widened to $220.478 million as of September 30, 2025, from $182.609 million at the end of 2024. Concurrently, cash and cash equivalents decreased to $2.395 million from $3.400 million, and total current assets fell significantly from $134.120 million to $71.805 million. This sharp decline in liquidity and worsening equity position poses a significant financial risk.
• Dependence on OMIDRIA Contract Royalty Asset [medium — operational]: The OMIDRIA contract royalty asset, both current and non-current, represents a substantial portion of the company's assets, totaling $124.083 million as of September 30, 2025. A decline in revenue or disputes related to this asset could materially impact the company's financial stability, given its current cash constraints.
• Clinical Trial Pauses and Regulatory Uncertainty [medium — regulatory]: Omeros has paused its Phase 3 clinical development program for zaltenibart in PNH. This decision, while strategic for capital allocation, introduces uncertainty regarding the future regulatory pathway and commercialization of this potential drug. Delays or failures in obtaining regulatory approval for key pipeline assets represent a significant risk.
• Significant Increase in Convertible Senior Notes [medium — financial]: The company issued $17.036 million in convertible senior notes that are current liabilities and $72.075 million non-current as of September 30, 2025. This new debt, coupled with existing term debt of $87.480 million non-current, increases financial leverage and future interest payment obligations, which could be burdensome given the company's net losses.
• Continued Net Losses and Burn Rate [high — financial]: Omeros reported a net loss of $30.917 million for Q3 2025 and $89.801 million for the nine months ended September 30, 2025. While an improvement from the prior year, the substantial ongoing losses indicate a significant cash burn rate that requires continuous funding, potentially through dilutive equity offerings or further debt.
• Execution Risk of Novo Nordisk Agreement [high — operational]: The successful closing and realization of the $340.0 million upfront and near-term milestone payments from the zaltenibart APLA with Novo Nordisk are critical. Any delays or failure to close the deal in Q4 2025, or challenges in achieving future milestones up to $1.71 billion, pose a substantial risk to the company's financial projections and operational plans.
• Competition in Therapeutic Areas [medium — market]: While specific competitors are not detailed in the provided text, Omeros operates in the biopharmaceutical sector, which is inherently competitive. The success of its products and pipeline depends on differentiating from existing treatments and emerging therapies, facing potential market share erosion or pricing pressures.
• Declining Short-Term Investments [medium — financial]: Short-term investments have decreased from $86.732 million at December 31, 2024, to $33.690 million as of September 30, 2025. This reduction, alongside the decrease in cash, suggests the utilization of these assets to fund operations, further highlighting the company's liquidity challenges.

Industry Context

Omeros operates in the highly competitive biopharmaceutical industry, characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. The sector is driven by innovation in drug discovery and the ability to navigate complex clinical trials and approval processes. Companies often rely on strategic partnerships and licensing agreements to fund development and access broader markets, especially when facing liquidity constraints.

Regulatory Implications

The pause in the Phase 3 zaltenibart program for PNH introduces regulatory uncertainty regarding its future development and potential market entry. Furthermore, any drug development faces rigorous scrutiny from regulatory bodies like the FDA, where failure to meet efficacy or safety standards can halt progress. The APLA with Novo Nordisk also implies adherence to specific regulatory milestones for future payments.

What Investors Should Do

1. Monitor the closing of the Novo Nordisk APLA in Q4 2025, as the $240.0 million payment is critical for Omeros's immediate liquidity.
2. Analyze the impact of the zaltenibart Phase 3 pause on the company's long-term pipeline value and future revenue projections.
3. Assess Omeros's ability to manage its cash burn rate and secure additional funding, given the low cash balance of $2.395 million and widening shareholders' deficit.
4. Evaluate the terms and potential success of achieving the $1.71 billion in future milestones from Novo Nordisk, which are contingent on zaltenibart's development and commercial success.
5. Consider the dilutive effects of increased common shares outstanding (up 12M shares YTD) on existing shareholders.

Key Dates

• 2025-10-10: Asset Purchase and License Agreement (APLA) signed with Novo Nordisk Health Care AG for zaltenibart. — This deal provides significant upfront and near-term payments ($240.0 million at closing) and potential future milestone payments, offering a crucial cash infusion and validation of the zaltenibart asset.
• 2025-Q4: Expected closing of the zaltenibart APLA with Novo Nordisk. — The closing is critical for Omeros to receive the initial $240.0 million payment, which is vital for its liquidity and funding of ongoing operations and other programs.
• 2025-09-30: Omeros Corporation's balance sheet date. — Reflects the company's financial position, including a reduced cash balance of $2.395 million and a widened shareholders' deficit of ($220.478 million).
• 2025-09-30: End of the nine-month period for financial reporting. — Shows a year-to-date net loss of $89.801 million, an improvement from the prior year, driven by reduced R&D and SG&A expenses.
• 2025-09-30: Common shares outstanding reached 70,073,622. — Represents a significant increase from 58,044,465 shares at December 31, 2024, indicating potential dilution from equity issuances.

Glossary

APLA

Asset Purchase and License Agreement. (This is the type of agreement Omeros entered into with Novo Nordisk for zaltenibart, outlining the terms of sale and licensing.)

Zaltenibart

A drug candidate developed by Omeros Corporation. (This is the asset subject to the significant APLA with Novo Nordisk, representing a key part of Omeros's strategic future.)

PNH

Paroxysmal Nocturnal Hemoglobinuria. (This is the indication for which Omeros was developing zaltenibart, and the Phase 3 program for which has been paused.)

OMIDRIA contract royalty asset

An asset representing future royalty payments or rights associated with the drug OMIDRIA. (This asset is a significant component of Omeros's balance sheet, contributing to its revenue and asset base.)

Convertible senior notes

Debt securities that can be converted into a predetermined amount of the issuer's equity. (Omeros has issued these notes, which represent a form of debt financing that could convert to equity, impacting share count and capital structure.)

Shareholders' deficit

A situation where a company's total liabilities exceed its total assets, resulting in a negative net worth. (Omeros currently has a shareholders' deficit, indicating its liabilities outweigh its assets, a common situation for development-stage biotechs but a sign of financial strain.)

Year-Over-Year Comparison

Compared to the prior year's filing (presumably for the period ending December 31, 2024, or Q3 2024), Omeros has significantly reduced its net losses both quarterly ($30.917M vs $32.232M) and year-to-date ($89.801M vs $125.457M), primarily due to decreased R&D and SG&A expenses. However, the company's financial position has weakened in terms of liquidity, with cash and cash equivalents dropping to $2.395M from $3.400M and total current assets falling substantially. A new risk factor has emerged with the issuance of convertible senior notes, increasing debt obligations. The company also faces the strategic challenge of a paused clinical program for zaltenibart, offset by the potential financial lifeline from the Novo Nordisk agreement.

Key Financial Figures

• $0.01 — h registered) Common Stock, par value $0.01 per share OMER The Nasdaq Stock Mar

Filing Documents

• omer20250930_10q.htm (10-Q) — 1551KB
• ex_856787.htm (EX-31.1) — 12KB
• ex_856788.htm (EX-31.2) — 13KB
• ex_856789.htm (EX-32.1) — 6KB
• ex_856790.htm (EX-32.2) — 6KB
• 0001437749-25-034826.txt ( ) — 8554KB
• omer-20250930.xsd (EX-101.SCH) — 78KB
• omer-20250930_def.xml (EX-101.DEF) — 560KB
• omer-20250930_lab.xml (EX-101.LAB) — 443KB
• omer-20250930_pre.xml (EX-101.PRE) — 586KB
• omer-20250930_cal.xml (EX-101.CAL) — 58KB
• omer20250930_10q_htm.xml (XML) — 1493KB

— Financial Information

Part I — Financial Information 5 Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) 5 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations and Comprehensive Loss 6 Condensed Consolidated Statements of Stockholders' Equity (Deficit) 7 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 23 Item 4.

Controls and Procedures

Controls and Procedures 23

— Other Information

Part II — Other Information 24 Item 1.

Legal Proceedings

Legal Proceedings 24 Item 1A.

Risk Factors

Risk Factors 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24 Item 3. Default Upon Senior Securities 24 Item 4. Mine Safety Disclosures 24 Item 5. Other Information 24 Item 6. Exhibits 25

Signatures

Signatures 26 Table of Contents

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS OMEROS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data) (unaudited) September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 2,395 $ 3,400 Short-term investments 33,690 86,732 OMIDRIA contract royalty asset 25,052 29,083 Receivables 6,908 7,739 Prepaid expense and other assets 3,760 7,166 Total current assets 71,805 134,120 OMIDRIA contract royalty asset, non-current 99,031 124,266 Right of use assets 11,807 14,961 Property and equipment, net 2,009 2,678 Restricted investments 1,054 1,054 Total assets $ 185,706 $ 277,079 Liabilities and shareholders' deficit Current liabilities: Accounts payable $ 12,499 $ 5,905 Accrued expenses 25,745 26,005 OMIDRIA royalty obligation 19,301 20,645 Convertible senior notes, net 17,036 — Term debt — 21,000 Lease liabilities 6,175 5,971 Total current liabilities 80,756 79,526 OMIDRIA royalty obligation, non-current 152,529 195,612 Convertible senior notes, non-current, net 72,075 97,178 Term debt, non-current, net 87,480 69,405 Lease liabilities, non-current 8,843 13,466 Other accrued liabilities, non-current 4,501 4,501 Commitments and contingencies (Note 10) Shareholders' deficit: Preferred stock, par value $ 0.01 per share, 20,000,000 shares authorized; none issued and outstanding at September 30, 2025 and December 31, 2024. — — Common stock, par value $ 0.01 per share, 150,000,000 shares authorized at September 30, 2025 and December 31, 2024; 70,073,622 and 58,044,465 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively. 700 580 Additional paid-in capital 778,968 727,156 Accumulated deficit ( 1,000,146 ) ( 910,345 ) Total shareholders' deficit ( 220,478 ) ( 182,609 ) Total liabilities and shareholders' deficit

View Full Filing

View this 10-Q filing on SEC EDGAR